Literature DB >> 23430545

Nutritional Changes and Micronutrient Supply in Patients with Phenylketonuria Under Therapy with Tetrahydrobiopterin (BH(4)).

A G Thiele1, J F Weigel2, B Ziesch2, C Rohde2, U Mütze2, U Ceglarek3, J Thiery3, A S Müller1, W Kiess2, S Beblo4.   

Abstract

BACKGROUND: Since 2008 patients with BH(4)-sensitive phenylketonuria can be treated with sapropterin dihydrochloride (Kuvan®) in addition to the classic phenylalanine (Phe) restricted diet. The aim of this study was to evaluate the nutritional changes and micronutrient supply in patients with phenylketonuria (PKU) under therapy with tetrahydrobiopterin (BH(4)). SUBJECTS AND METHODS: 19 children with PKU (4-18 years) and potential BH(4)-sensitivity were included, 14 completed the study protocol. Dried blood Phe concentrations as well as detailed dietary records were obtained throughout the study at preassigned study days.
RESULTS: Eight patients could increase their Phe tolerance from 629 ± 476 mg to 2131 ± 1084 mg (P = 0.006) under BH(4) while maintaining good metabolic control (Phe concentration in dried blood 283 ± 145 μM vs. 304 ± 136 μM, P = 1.0), therefore proving to be BH(4)-sensitive. They decreased their consumption of special low protein products and fruit while increasing their consumption of high protein foods such as processed meat, milk and dairy products. Intake of vitamin D (P = 0.016), iron (P = 0.002), calcium (P = 0.017), iodine (P = 0.005) and zinc (P = 0.046) significantly declined during BH(4) treatment while no differences in energy and macronutrient supply occurred.
CONCLUSION: BH(4)-sensitive patients showed good metabolic control under markedly increased Phe consumption. However, the insufficient supply of some micronutrients needs consideration. Long-term multicenter settings with higher sample sizes are necessary to investigate the changes of nutrient intake under BH(4) therapy to further evaluate potential risks of malnutrition. Supplementation may become necessary.

Entities:  

Year:  2012        PMID: 23430545      PMCID: PMC3565664          DOI: 10.1007/8904_2012_176

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  30 in total

1.  Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life.

Authors:  B Ziesch; J Weigel; A Thiele; U Mütze; C Rohde; U Ceglarek; J Thiery; W Kiess; S Beblo
Journal:  J Inherit Metab Dis       Date:  2012-03-06       Impact factor: 4.982

2.  Behaviour and school achievement in patients with early and continuously treated phenylketonuria.

Authors:  B A Stemerdink; A F Kalverboer; J J van der Meere; M W van der Molen; J Huisman; L W de Jong; F M Slijper; P H Verkerk; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

3.  Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study.

Authors:  P Burgard; F Rey; A Rupp; V Abadie; J Rey
Journal:  Pediatr Res       Date:  1997-03       Impact factor: 3.756

4.  Nutrient intake and food consumption of adolescents and young adults with phenylketonuria.

Authors:  B Schulz; H J Bremer
Journal:  Acta Paediatr       Date:  1995-07       Impact factor: 2.299

5.  Validation of the phenylalanine/tyrosine ratio determined by tandem mass spectrometry: sensitive newborn screening for phenylketonuria.

Authors:  Uta Ceglarek; Peter Müller; Barbara Stach; Peter Bührdel; Joachim Thiery; Wieland Kiess
Journal:  Clin Chem Lab Med       Date:  2002-07       Impact factor: 3.694

6.  Parenting style and adolescent fruit consumption.

Authors:  Stef P J Kremers; Johannes Brug; Hein de Vries; Rutger C M E Engels
Journal:  Appetite       Date:  2003-08       Impact factor: 3.868

7.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

8.  Hyperphenylalaninemia due to a deficiency of biopterin. A variant form of phenylketonuria.

Authors:  S Kaufman; S Berlow; G K Summer; S Milstien; J D Schulman; S Orloff; S Spielberg; S Pueschel
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

9.  Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria.

Authors:  Ania C Muntau; Wulf Röschinger; Matthias Habich; Hans Demmelmair; Björn Hoffmann; Christian P Sommerhoff; Adelbert A Roscher
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

10.  Free use of fruits and vegetables in phenylketonuria.

Authors:  A MacDonald; G Rylance; P Davies; D Asplin; S K Hall; I W Booth
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.750

View more
  11 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  PKU patients on a relaxed diet may be at risk for micronutrient deficiencies.

Authors:  C Rohde; A von Teeffelen-Heithoff; A G Thiele; M Arelin; U Mütze; C Kiener; J Gerloff; C Baerwald; S Schultz; C Heller; A S Müller; W Kiess; S Beblo
Journal:  Eur J Clin Nutr       Date:  2013-11-20       Impact factor: 4.016

Review 3.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 4.  Recommendations for the nutrition management of phenylalanine hydroxylase deficiency.

Authors:  Rani H Singh; Fran Rohr; Dianne Frazier; Amy Cunningham; Shideh Mofidi; Beth Ogata; Patricia L Splett; Kathryn Moseley; Kathleen Huntington; Phyllis B Acosta; Jerry Vockley; Sandra C Van Calcar
Journal:  Genet Med       Date:  2014-01-02       Impact factor: 8.822

5.  Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet.

Authors:  Hala M Koura; Sherif M Zaki; Nagwa A Ismail; Emad E Salama; Dalia H El Lebedy; Laila K Effat
Journal:  Iran J Pediatr       Date:  2013-12-31       Impact factor: 0.364

6.  Biomarkers of Micronutrients in Regular Follow-Up for Tyrosinemia Type 1 and Phenylketonuria Patients.

Authors:  Kimber van Vliet; Iris L Rodenburg; Willem G van Ginkel; Charlotte M A Lubout; Bruce H R Wolffenbuttel; Melanie M van der Klauw; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Nutrients       Date:  2019-08-27       Impact factor: 5.717

7.  The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: Effects on metabolic control, nutritional habits and nutrient supply.

Authors:  Alena G Thiele; Carmen Rohde; Ulrike Mütze; Maria Arelin; Uta Ceglarek; Joachim Thiery; Christoph Baerwald; Wieland Kiess; Skadi Beblo
Journal:  Mol Genet Metab Rep       Date:  2015-07-26

8.  One-year follow-up of B vitamin and Iron status in patients with phenylketonuria provided tetrahydrobiopterin (BH4).

Authors:  Kristen D Brantley; Teresa D Douglas; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2018-10-30       Impact factor: 4.123

9.  Optimising amino acid absorption: essential to improve nitrogen balance and metabolic control in phenylketonuria.

Authors:  Anita MacDonald; Rani H Singh; Júlio César Rocha; Francjan J van Spronsen
Journal:  Nutr Res Rev       Date:  2018-10-04       Impact factor: 7.800

Review 10.  Protein Substitute Requirements of Patients with Phenylketonuria on BH4 Treatment: A Systematic Review and Meta-Analysis.

Authors:  Fatma Ilgaz; Cyril Marsaux; Alex Pinto; Rani Singh; Carmen Rohde; Erdem Karabulut; Hülya Gökmen-Özel; Mirjam Kuhn; Anita MacDonald
Journal:  Nutrients       Date:  2021-03-23       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.